Therapeutic drug monitoring · 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vidal-Alabró Anna, Fontova Pere, Mohammed Ali Zeyar, Fernández-Alarcón Beatriz, Cerezo Gema, Melilli Edoardo, Montero Nuria, Coloma Ana, Manonelles Anna, Favà Alexandre, Codina Sergi, Couceiro Carlos, Oliveras Laia, Torras Joan, Grinyó Josep M, Cruzado Josep M, Colom Helena, Lloberas Nuria
Аннотация
BACKGROUND: Tacrolimus is the most commonly used immunosuppressant drug in solid organ transplant recipients. Different formulations of tacrolimus have distinct pharmacokinetic profiles due to differences in absorption and elimination. This study aimed to investigate the influence of CYP3A5 polymorphisms on tacrolimus exposure after conversion from immediate-release tacrolimus (Tac-IR) to prolonged-release tacrolimus (Tac-LCP) in stable kidney transplant recipients.
METHODS: Intensive pharmacokinetic sampling was performed in 19 kidney transplant recipients before and 1 month after switching from Tac-IR to Tac-LCP. Patients were genotyped for CYP3A5 polymorphisms.
RESULTS: Patients expressing CYP3A5*1 required a significantly higher dose of Tac-IR than nonexpressers to achieve similar predose concentrations (C 0 ), maximum concentrations (C max ), and area-under-the-curve values (AUC 0-24h ). After switching to Tac-LCP, CYP3A5*1 expressers had similar C 0 values but significantly higher C max and AUC 0-24h values compared with nonexpressers . Dose-normalized exposure showed that CYP3A5*1 expressers had a lower conversion rate than nonexpressers (0.58 versus 0.807).
CONCLUSIONS: These results suggest that CYP3A5 genotype should be considered when adjusting the tacrolimus dose during conversion from Tac-IR to Tac-LCP. C 0 values may not adequately reflect the higher exposure observed in CYP3A5*1 expressers , highlighting the importance of AUC 0-24 h in guiding dose adjustment.
METHODS: Intensive pharmacokinetic sampling was performed in 19 kidney transplant recipients before and 1 month after switching from Tac-IR to Tac-LCP. Patients were genotyped for CYP3A5 polymorphisms.
RESULTS: Patients expressing CYP3A5*1 required a significantly higher dose of Tac-IR than nonexpressers to achieve similar predose concentrations (C 0 ), maximum concentrations (C max ), and area-under-the-curve values (AUC 0-24h ). After switching to Tac-LCP, CYP3A5*1 expressers had similar C 0 values but significantly higher C max and AUC 0-24h values compared with nonexpressers . Dose-normalized exposure showed that CYP3A5*1 expressers had a lower conversion rate than nonexpressers (0.58 versus 0.807).
CONCLUSIONS: These results suggest that CYP3A5 genotype should be considered when adjusting the tacrolimus dose during conversion from Tac-IR to Tac-LCP. C 0 values may not adequately reflect the higher exposure observed in CYP3A5*1 expressers , highlighting the importance of AUC 0-24 h in guiding dose adjustment.